CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Novo Nordisk is planning a major India launch of its blockbuster weight-loss drug Wegovy, aiming for Rs 8,600 crore in sales within 5–7 years. The company eyes top spot in prescription drug sales with ...

Novo Nordisk has introduced Wegovy, a once-weekly weight loss injection, in India. The drug aims to manage obesity and reduce ...

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.

Danish pharma giant Novo Nordisk’s announcement comes months after the launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

They have been called miraculous and the fastest way to lose weight. From Wegovy to Mounjaro, here’s how GLP-1 drugs work ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.